State-of-the-art biological therapy of rheumatoid arthritis

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 6, 2008, Pages 19-24

  Sigidin, Ya A ^a   Lukina, G V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48449107193     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Russian source
2. Russian source
3. Ostergaard M., Unkerskow J., Krogh N. S. et al. Poor remission rates but long drug survival in rheumatois arthritis patients treated with infliximab or etanercept - results from the nationwide danish "danbio" database. Ann. Rheum. Dis. 2005; 64: 59-60.
4. Gomez-Reino J. J., Dasgupta B., Haugeberg G. et al. Mortality rate is reduced in RA patients treated with TNF antagonists. Data from Biobadaser. Ann. Rheum. Dis. 2006; 65 (suppl. II): 318.
5. Hochberg M., Tracy J., Hawkins-Holt M., Flores R. Comparison of efficacy of tumor necrosis factor a blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62 (suppl. II): ii13-ii16.
6. Deane K, West S. Early, aggressive RA therapy: addressing the safety issues. J. Musculoskel. Med. 2006; 23: 240-250.
7. Erra A., Moreno E., Guanhon L. et al. Experience in the switch from infliximab to etanercept, or vica versa, in rheumatoid arthritis patients. Ann. Rheum. Dis. 2002; 61 (suppl. 1): 379.
8. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J. Rheumatol. 2004; 31: 1021-1022.
9. Singh A., Nab H. A meta-analysis of biological response modifiers in the treatment of rheumatoid arthritis for patients failing one or more disease modifying drugs. Ann. Rheum. Dis. 2003; 62 (suppl. I): 185-186.
10. Buch M. H., Bingham S. J., Bejanaro V. et al. Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthr. Care Res. 2007; 57: 448-453.
11. Nishimoto N., Yoshizaki K., Miyasaka N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthr. and Rheum. 2004; 50: 1761-1769.
12. Russian source
13. Russian source
14. Sigidin Ya. A., Loukina G. V., Skurkovich B., Skurkovich S. Randomized, double-blind trial of anti-interferon-y antibodies in rheumatoid arthritis. Scand. J. Rheumatol. 2001; 30: 203-207.
15. Skurkovich S., Boiko A., Beliaeva I. et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Multiple. Scleras. 2001; 7: 277-284.
16. Russian source
17. Russian source
18. Skurkovich S. V., Volkov I. E., Delyagin V. M. et al. First use of anti-interferon (IFN)-γ in the treatment of type I diabetes in children. In: 8-th International workshop on autoantibodies and autoimmunity. Berlin; 2003. abstr. 12.
19. Skurkovich S. V., Delyagin V. M., Rumyantsev A. G. et al. Anti-IFN-γ in the treatment of rheumatoid arthritis-associated uveitis in children. In: 8-th International workshop on autoantibodies and autoimmunity. Berlin: 2003, abstr. 18.
20. Hommes D. W., Mikhajlova T. L., Stoinov S. et al. Fontouzumab, a humanized anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 56: 1131-1137.
21. Emery P., Westhovens R., Moreland L. et al. CTLA4-Ig (BMS-18866) in a phase IIB, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methotrexate showed correlation between the clinical response and key biomarkers. Ann. Rheum. Dis. 2003; 62 (suppl. 1): 409.
22. Bich M., Boyle D., Saleem B. et al. The selective co-stimulation modulator abatacept decreases synovial inflammation and expression of pro-inflammatory cytokines in patients with rheumatoid arthritis. Arth. and Rheum. 2005; (suppl. 1) 446.
23. Russell A., Kremer J., Zhou Y. et al. Abatacept induces sustained improvement in physical function and pain over 3 years in RA patients with inadequate responses to methotrexate. Arthr. and Rheum. 2005; 52 (suppl.): 659.
24. Finckh A., Ciurea A., Brulhart L. et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor agent. Arthr. and Rheum. 2007; 56: 1417-1432.
25. Keystone E., Emery P., Peterfy C. G. et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). Ann. Rheum. Dis. 2006; 65 (suppl. II): 58.
26. Smolen J. S., Keystone E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 143-159.
27. Saito K, Nawato M., Nakayamada S. et al. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798-200.
28. Russian source
29. Taylor M., Trueman P., Conway P. et al. Economic benefits of etanercept for achieving clinical and radiographic remission in patients with rheumatoid arthritis: using TEMPO data. Ann. Rheum. Dis. 2006: 65 (suppl. II): 505.